OKYO Pharma to Present Urcosimod Data, Seek SAB Guidance at ASCRS Meeting
Event summary
- OKYO Pharma will hold a Scientific Advisory Board (SAB) meeting during the 2026 ASCRS Annual Meeting in Washington, DC.
- Dr. Pedram Hamrah will present Phase 2 data on urcosimod for neuropathic corneal pain (NCP) at the ASCRS meeting on April 11, 2026.
- Urcosimod has received Fast Track designation from the FDA for treating NCP.
- OKYO plans to initiate a 150-patient Phase 2b/3 trial for urcosimod in the first half of 2026.
The big picture
OKYO Pharma is positioning itself as a key player in the treatment of neuropathic corneal pain, a condition with significant unmet medical needs. The company’s strategic engagement with top ophthalmology experts and the FDA’s Fast Track designation for urcosimod highlight its aggressive push to bring a first-of-its-kind therapy to market. The upcoming Phase 2b/3 trial will be critical in validating urcosimod’s efficacy and safety profile, potentially setting the stage for a competitive advantage in the ophthalmology space.
What we're watching
- Clinical Strategy
- How the SAB meeting will refine OKYO’s approach to the upcoming Phase 2b/3 trial for urcosimod.
- Regulatory Momentum
- Whether the Fast Track designation will accelerate urcosimod’s path to market approval.
- Market Differentiation
- The pace at which OKYO can establish urcosimod as a leading therapy for NCP in a space with no FDA-approved treatments.